Publications by authors named "Giovanni L Pastorino"
Purpose Of Review: Muscle invasive bladder cancer (MIBC) is aggressive and requires radical cystectomy and neoadjuvant therapy, yet over 40% of patients face recurrence. The loss of the bladder also significantly reduces quality of life. Accurate staging, crucial for treatment decisions, is typically done through transurethral resection (TURBT), but inconsistencies in pathology affect diagnosis in 25% of cases.
View Article and Find Full Text PDFFirst Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.
Chiara Mercinelli Marco Moschini Antonio Cigliola Benedetta Mattorre Valentina Tateo Giovanni L Pastorino
J Clin Oncol
December 2024
Article Synopsis
- The study aimed to assess the effectiveness and safety of combining nivolumab with nab-paclitaxel as a pre-surgery treatment for patients with muscle-invasive bladder cancer (MIBC), followed by surgery and additional nivolumab therapy.
- A total of 31 patients participated, with a significant portion experiencing severe treatment-related side effects; however, the treatment led to a notable pathologic complete response rate of 32.3% among those evaluated.
- The findings indicate promising outcomes with an 89.8% event-free survival rate after 12 months, suggesting this combination therapy could enhance treatment options for these patients.